CARLSMED, INC.
No enriched coverage for $CARL in the last 7 days.
Carlsmed, Inc. (CARL) has launched its aprevo Lumbar Bi-lateral Posterior System in the U.S. after a limited market evaluation. The company announced this at the North American Spine Society (NASS) event. Carlsmed aims to expand its personalized spine platform with this new product.
Carlsmed (NASDAQ:CARL) appointed Tony Jarc as chief product and AI officer to expand its AI-powered, patient-specific implant business. The company also recently added a CFO and promoted a COO. Medicare reimbursements for Carlsmed's Aprevo lumbar fusion procedures began October 1.
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Carlsmed Appoints Richard Heppenstall as Chief Financial Officer Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., September 28, 2026 (GLOBE NEWSWIRE) – Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering A
Recent CARL coverage spans financial news, corporate actions and earnings.
In the last 30 days, CARL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($14K). The most active reporter was Bertolini Jeffrey, Chief Operating Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The launch adds a new product line, likely generating modest upside as the company expands its spine platform.
The executive hire signals a push into AI-driven spine surgery, while new Medicare coverage could lift revenue.
The appointment signals continuity in finance leadership while the reaffirmed guidance supports the current valuation outlook.
Executive promotion may improve operational execution and support scaling of AI‑enabled spine surgery platform.
CMS MS-DRG code changes are a reimbursement tailwind narrative, but management explicitly guides no material impact on 2H 2026 results; near-term focus stays on launches and cost/margin trajectory.
AlphAI scores every news story that mentions CARL with an AI model for sentiment and relevance, and aggregates insider trades from CARLSMED, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Carlsmed, Inc. (CARL) has launched its aprevo Lumbar Bi-lateral Posterior System in the U.S. after a limited market evaluation. The company announced this at the North American Spine Society (NASS) event. Carlsmed aims to expand its personalized spine platform with this new product.
1 min readCarlsmed (NASDAQ:CARL) appointed Tony Jarc as chief product and AI officer to expand its AI-powered, patient-specific implant business. The company also recently added a CFO and promoted a COO. Medicare reimbursements for Carlsmed's Aprevo lumbar fusion procedures began October 1.
2 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Carlsmed Appoints Richard Heppenstall as Chief Financial Officer Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., September 28, 2026 (GLOBE NEWSWIRE) – Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering A
1 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Carlsmed, Inc. Announces Chief Operating Officer Appointment CARLSBAD, Calif., September 8, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announc
1 min readCarlsmed (NASDAQ:CARL) discussed a CMS final rule issued July 31 that creates new MS-DRG codes for aprevo lumbar procedures, effective Oct. 1, 2026, replacing 11 codes. Management expects no material impact on 2H 2026 results. Q2 gross margin rose to 76.8% and GAAP net loss widened to $10.5M. Cash and investments were $89.3M at June 30.
5 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, CALIFORNIA, AUGUST 5, 2026 (G
4 min readThe article provides financial information for Carlsmed, Inc. (LS:A41CM7) on TradingView. It shows the total operating expenses for the company, accessible through various financial data providers like ICE Data Services and FactSet. The content primarily focuses on the display of operating expenses within the TradingView platform.
2 min readThis page provides financial statistics for Carlsmed, Inc. (LS:A41CM7), a company listed on the Lang & Schwarz Tradecenter. It details various annual and quarterly key financial stats and ratios, including valuation, profitability, liquidity, solvency ratios, and per-share metrics, although most data fields are currently listed as unavailable. The page serves as a hub for users to find market capitalization, P/E Ratio, EPS, ROI, and other financial information for Carlsmed.
2 min readCarlsmed, Inc. (NASDAQ:CARL) experienced a significant 26.4% drop in short interest in April, with the total short interest falling to 571,356 shares. Institutional investors have increased their holdings in the company, with OrbiMed Advisors LLC, Janus Henderson Group PLC, and Vanguard Group Inc. initiating or adding to their positions. Despite a "Hold" consensus rating and a target price of $19.67, analyst sentiment is mixed, with some firms trimming price targets while others maintain "Buy" ratings.
2 min readCarlsmed, Inc. (NASDAQ:CARL) has received a consensus "Hold" recommendation from five brokerages. The average 1-year price target is $21.33, with institutional investors recently increasing their stakes. The company's stock traded up 15.9% and beat quarterly earnings estimates.
3 min read
